Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Aarthi Jayanthan | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 9 años |
Janet Grove | F | 57 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Julia G. Levy | M | 89 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Magda Marquet | M | 65 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 5 años |
Steven J. Potts | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Christopher Bissonnette | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 6 años |
Lana Janes | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
David A. Schellenberg | M | 60 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Alan Ashworth | M | 63 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Robert Levak | M | - |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | 3 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David Crean | M | 59 |
Phoenix Molecular Designs Ltd.
Phoenix Molecular Designs Ltd. Miscellaneous Commercial ServicesCommercial Services Phoenix Molecular Designs operates as a biopharmaceutical company. It focuses on developing first-in-class inhibitors against ribosomal S6 kinase (RSK), an important drug target for cancer, heart disease, and inflammation. The company was founded by Sandra Dunn in 2012 and is headquartered in Vancouver, Canada. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Canadá | 11 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Sandra E. Dunn
- Red Personal